Scientists develop test for uncommon brain diseases

Samples of cerebrospinal fluid used to detect tauopathies

Date:: October 16, 2019
Source:: NIH/National Institute of Allergy and Infectious Diseases
Summary:: Scientists have developed an ultrasensitive new test to detect abnormal forms of the protein tau associated with uncommon types of neurodegenerative diseases called tauopathies. This advance gives them hope of using cerebrospinal fluid, or CSF -- an accessible patient sample -- to diagnose these and perhaps other, more common neurological diseases, such as Alzheimer's disease.
Share:: Facebook Twitter Pinterest LinkedIN Email

FULL STORY

国立卫生研究院(NIH)科学家甲型肝炎e developed an ultrasensitive new test to detect abnormal forms of the protein tau associated with uncommon types of neurodegenerative diseases called tauopathies. As they describe inActa Neuropathologica, this advance gives them hope of using cerebrospinal fluid, or CSF -- an accessible patient sample -- to diagnose these and perhaps other, more common neurological diseases, such as Alzheimer's disease.

Scientists have linked the abnormal deposition of tau in the brain to at least 25 different neurodegenerative diseases. However, to accurately diagnose these diseases, brain tissue often must be analyzed after the patient has died.

For their study, the researchers used the same test concept they developed when using post-mortem brain tissue samples to detect the abnormal tau types associated with Pick disease, Alzheimer's disease and chronic traumatic encephalopathy (CTE). They adapted the test to use CSF for the detection of abnormal tau of progressive supranuclear palsy (PSP), corticobasal degeneration (CBD), and other less common tauopathies.

They detected abnormal tau in CSF from both living and deceased patients. In one case, the test led to a corrected diagnosis in a patient who had died from CBD, but who was initially diagnosed with PSP. The new test is called 4R RT-QuIC -- which stands for 4-repeat tau protein amplified in a real-time, quaking-induced conversion process.

The test was developed at NIH's Rocky Mountain Laboratories, part of the National Institute of Allergy and Infectious Diseases. Study collaborators, who provided patient specimens and clinical guidance, included investigators from the Mayo Clinic in Jacksonville, Florida; the University of Bologna, Italy; the University of California, San Diego; the University of California, San Francisco; Indiana University; and the University of Verona in Italy.

The researchers plan to continue evaluating the clinical performance of 4R RT-QuIC by analyzing larger sets of CSF samples. One focus will be to compare test results from tauopathy patients who agree to provide CSF samples both before and after death. The scientists hope this type of evaluation will help them better understand how abnormal tau in CSF evolves during brain disease.